Healthdirect Free Australian health advice you can count on.

Medical problem? Call 1800 022 222. If you need urgent medical help, call triple zero immediately

healthdirect Australia is a free service where you can talk to a nurse or doctor who can help you know what to do.

beginning of content

Brand name: Bicnu

Bicnu is a medicine containing the active ingredient(s) carmustine. On this page you will find out more about Bicnu, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)

You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.

Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.

Active ingredient in this medicine: carmustine

Information for medicine and pack size:
Bicnu (10 x 100 mg vials, 10 x 3 mL inert diluent vials), 1 pack

Consumer Medicine Information leaflet:

This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.

Read leaflet

What this medicine is for

INDICATIONS AS AT 16 DECEMBER 1985: Carmustine is indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in the following: 1. Malignant Glioma. 2. Multiple Myeloma: In combination with prednisone. 3. Hodgkin's Disease: As secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy. 4. Non-Hodgkins lymphomas: As secondary therapy in combination with other approved drugs for patients who relapse while being treated with primary therapy or who fail to respond to primary therapy.

Table of characteristics
Table of characteristics
Active ingredient
Medicine schedule
1 vial of powder - 100mg each: Prescription Only Medicine, or Prescription Animal Remedy
10 vials of powders - 100mg each: Prescription Only Medicine, or Prescription Animal Remedy
1 vial of diluent - 3mL each: Not scheduled. Not considered by committee
10 vials of diluent - 3mL each: Not scheduled. Not considered by committee
Part 1
Part 1
Visual appearance Pale yellow powder
Dosage Form Injection, powder for
Route of administration Intravenous
Part 2
Part 2
Visual appearance Clear colourless liquid
Dosage Form Diluent, not applicable
Route of administration Intravenous

There is one type of pack available.

Pack type 1
Pack type 1
Type Multiple containers
Storage temperature Store at 2 to 8 degrees Celsius
Storage conditions Do not Freeze,Refrigerate
Life time 36 Months
We were unable to verify that this medicine is available on the PBS (Pharmaceutical Benefits Scheme). Please consult your pharmacist if you need further information

The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.

Go to PBS site

Is this medication banned in sport?

Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.

Go to ASADA site

The information displayed on this page is authored by Healthdirect Australia, or obtained from trusted sources.

Need more information?

These trusted information partners have more on this topic.

Found 2 results


Carmustine is used in the palliative management, alone or in combination with other agents, of the following cancers: malignant glioma (type of brain tumour) multiple myeloma (often in combination with prednisone) Hodgkins disease Non-Hodgkins lymphoma The implantable preparation of Carmustine, Gliadel Implant, is used to prolong life in patients with recurrent glioblastoma multiforme (a malignant brain tumour) who have had surgery

Read more on myVMC – Virtual Medical Centre website

BiCNU Powder for injection -

BiCNU Powder for injection - Consumer Medicines Information leaflets of prescription and over-the-counter medicines

Read more on myDr – Consumer Medicine Information website

Healthdirect 24hr 7 days a week hotline

24 hour health advice and information you can count on

1800 022 222

Government Accredited with over 140 information partners

We are a government-funded service, providing quality, approved health information

Australian Government, health department logo ACT Government logo New South Wales government, health department logo Northen Territory Government logo Government of South Australia, health department logo Tasmanian government logo Government of Western Australia, health department logo